Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Screening for prostate cancer
Dragan Ilic
, Molly M. Neuberger
, Mia Djulbegovic
,
Philipp Dahm
Urology
Research output
:
Contribution to journal
›
Review article
›
peer-review
302
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Screening for prostate cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Prostate Cancer
100%
Prostate Cancer Risk
100%
Confidence Interval
72%
Risk Ratio
63%
Randomized Controlled Trial
54%
European Randomized Study of Screening for Prostate Cancer
54%
Meta-analysis
45%
Prostate Cancer Screening
36%
Prostate
27%
Risk of Bias
27%
Control Risk
27%
Lung
18%
All-cause Mortality
18%
Quality of Life
18%
Bleeding
18%
Cancer Study
18%
Adverse Events
18%
Prostate-specific Antigen Testing
18%
Digital Rectal Examination
18%
Overall Mortality
18%
Overtreatment
18%
Screening Risks
18%
Erectile Dysfunction
9%
Lung Cancer Screening
9%
Health Policy
9%
Patient Preference
9%
Pneumonia
9%
High Risk
9%
Treatment-related
9%
Ovarian Cancer Screening
9%
Colorectal Cancer Screening
9%
Low Risk
9%
Incontinence
9%
Subgroup Analysis
9%
Adverse Effects
9%
Blood Loss
9%
Comprehensive Assessment
9%
False-positive Results
9%
Advanced Prostate Cancer
9%
Mortality Risk
9%
Transfusion
9%
Quality of Life Impact
9%
Localized Prostate Cancer
9%
Policy Decisions
9%
Prostate-specific Antigen
9%
Life Expectancy
9%
No Significant Difference
9%
Diagnostic Evaluation
9%
Sensitivity Analysis
9%
MEDLINE
9%
Embase
9%
Significant Benefit
9%
Search Methods
9%
Resource Utilization
9%
Inclusion Criteria
9%
Life Events
9%
Selection Criteria
9%
Biopsy Techniques
9%
Disease-specific Mortality
9%
Transrectal Biopsy
9%
National Policy
9%
Methodological Quality
9%
Cochrane Central Register of Controlled Trials
9%
Absence of Evidence
9%
Medical Organization
9%
Group Risk
9%
Overall Risk
9%
Data Risk
9%
Risk-benefit Ratio
9%
Cochrane Review
9%
Opportunistic Screening
9%
Bruise
9%
Selective Screening
9%
Decision-making Policies
9%
Text Reviews
9%
Trial Data
9%
Updated Data
9%
Medicine and Dentistry
Prostate Cancer
100%
Specific Mortality
34%
Randomized Controlled Trial
20%
Meta-Analysis
17%
Quality of Life
10%
Overdiagnosis
10%
Lung
6%
Infection
6%
All Cause Mortality
6%
Systematic Review
6%
Adverse Event
6%
Bleeding
6%
Prostate Specific Antigen
6%
Biopsy Technique
6%
Digital Rectal Examination
6%
Cancer Screening
6%
Lung Cancer Screening
3%
High Risk Population
3%
Incontinence
3%
Colorectal Cancer Screening
3%
Subgroup Analysis
3%
Ovarian Cancer Screening
3%
Patient Decision Making
3%
Life Expectancy
3%
False Positive Result
3%
Life Event
3%
Transrectal Ultrasonography
3%
Erectile Dysfunction
3%
Prostate Specific Antigen Test
3%
Risk-Benefit Ratio
3%
Isoprenaline
3%
Diseases
3%
Adverse Effect
3%
Nursing and Health Professions
Prostate Cancer
100%
Confidence Interval
27%
Meta Analysis
17%
Prostate Specific Antigen
10%
Quality of Life
10%
Systematic Review
6%
Infection
6%
Bleeding
6%
Adverse Event
6%
All Cause Mortality
6%
Digital Rectal Examination
6%
Biopsy Technique
6%
Cancer Screening
6%
Health Care Policy
3%
Cochrane Library
3%
Medline
3%
Ovary Cancer
3%
Embase
3%
Incontinence
3%
Life Expectancy
3%
High Risk Population
3%
Isoprenaline
3%
False Positive Result
3%
Erectile Dysfunction
3%
Transrectal Ultrasonography
3%
Diseases
3%
Decision-Making
3%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Randomized Controlled Trial
20%
Prostate Specific Antigen
10%
Infection
6%
All Cause Mortality
6%
Bleeding
6%
Adverse Event
6%
Erectile Dysfunction
3%
Ovary Cancer
3%
Incontinence
3%
Life Expectancy
3%
Isoprenaline
3%
Diseases
3%